Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

Let us refresh the old gold Buddhist tale of The Quail and the Net: ldquo;Long ago a flock of quails lived in a forest .

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...

New World Health Organisation (WHO) recommendations for the use of long-acting HIV prevention and treatment are a welcome boost in the global efforts to end ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.